This study was terminated in Germany. It is testing naltrexone for Borderline Personality Disorder.
Personality disorders, Borderline personalityDrugFrom 18 Years to 50 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States may be useful for adults experiencing personality disorders.
What would participation involve?
Participants may receive the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States, attend study visits with the research team. The registry lists locations in Germany.
Who is it mainly for?
This study appears to be mainly for adults with personality disorders.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateOctober 2005
Recruitment status
Terminated
Enrollment listed in the registry
48
Sponsor
Central Institute of Mental Health, Mannheim
Sponsor type
Research institute
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Germany
Age range
From 18 Years to 50 Years
Official registry ID
NCT00124839
Official title
Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00124839. We help you review the study, but cannot decide medical eligibility.
Recruitment & locations
Terminated
Mannheim · Bad Wiessee · Simbach
2 more locations
Rostock
Cologne
Registry details
Registry conditions (original wording)
Borderline Personality Disorder
FAQ
Questions about this study
Who is behind this study?
The study sponsor is Central Institute of Mental Health, Mannheim.
Does this study involve medication?
The study includes Naltrexone.
Who can participate?
Listed age limits: 18 years to 50 years.
Is this study still recruiting?
The registry lists this study as terminated.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
